RecruitingLocally Advanced / Metastatic Solid Tumors
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
11 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with locally advanced or metastatic solid tumors.
Sponsor: Crescent Biopharma, Inc.
Where it's recruiting
Source: ClinicalTrials.gov · NCT07335497 · last updated 2026-07-29